Daily Stock Setups

Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population

Posted on: Tue, 17 Nov 2009 11:25:00 EST

Symbols: SVA

Are you looking to increase your ETF knowledge?

BEIJING, Nov 17, 2009 /PRNewswire-Asia via COMTEX/ --
SVA | Quote | Chart | News | PowerRating -- Sinovac Biotech Ltd. (Nasdaq: SVA),
a leading developer and provider of vaccines in China, announced today that it
received a revised production license from State Food and Drug Administration
for Panflu.1, the Company's H1N1 vaccine. The population has been expanded to
include people over 60 years old. The shelf life for PANFLU.1 was extended to
one year from six months.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "The
revised license enables Sinovac to provide our H1N1 vaccine to a broader
population across China and lengthens the product shelf life. We continue to
work closely with Chinese government to provide citizens with
international-quality vaccines and to fulfill our mission of supplying
vaccines to eliminate human diseases."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's vaccine
products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and
B), and Anflu(R) (influenza). PANFLU.1(TM), Sinovac's H1N1 vaccine, and
Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), have already been
approved for government stockpiling. Sinovac is developing vaccines for
enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine,
and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is has
submitted an application for approval with the Ministry of Agriculture for its
independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.


    For further information, please contact:

    Sinovac Biotech Ltd.
     Helen G. Yang
     Tel:  +86-10-8289-0088 x9871
     Fax:  +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
    The Ruth Group
     Amy Glynn/Stephanie Carrington
     Tel:  +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media
    The Ruth Group
     Janine McCargo
     Tel:    +1-646-536-7033
     Email:  jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.

http://www.sinovac.com

For full details on Sinovac Biotech Ltd (SVA) SVA. Sinovac Biotech Ltd (SVA) has Short Term PowerRatings at TradingMarkets. Details on Sinovac Biotech Ltd (SVA) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.